Oncology Central

Targeting BRAF mutations to treat ovarian cancer

A team of researchers have demonstrated that low-grade serous cancer (LGSC) patients with a BRAF mutation gene respond well to treatment with BRAF inhibitors.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.